Biotech News

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Pharmaceuticals, Inc. (ELDN)Eledon Pharmaceuticals, Inc.Conference / presentation

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation.

Details of the presentation are below:

Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients

Presenter: Andrew B. Adams, M.D., Ph.D., Department of Surgery, University of Minnesota Medical School; Minneapolis, Minnesota

Abstract Publication Number: FR-OR084

Session Title: The Changing Landscape of Kidney Transplantation: Clinical Innovation, Outcomes, and Healthy Policy

Session Date and Time: Friday, October 23, 2026, from 4:30PM to 6:00PM MDT

Session Room: Mile High Ballroom 4A (Convention Center)

Presentation Time: 4:40PM to 4:50 PM MDT

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com .

Follow Eledon Pharmaceuticals on social media: LinkedIn ; X

Investor Contact:

Stephen Jasper Gilmartin Group (858) 525 2047 [email protected]

Media Contact:

Jenna Urban CG Life (212) 253 8881 [email protected]

Related news

ELDNEledon Pharmaceuticals, Inc.2026-09-09 11:00 EST

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

KNSAKiniksa2026-11-11 21:01 EST

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

VERAVera Therapeutics2026-10-02 13:24 EST

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

IFRXInflarx NV2026-10-22 16:00 EST

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

ELDNEledon Pharmaceuticals, Inc.2026-09-22 11:00 EST

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

XFORX4 Pharmaceuticals2026-09-09 11:00 EST

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

GPCRStructure Therapeutics2026-11-04 12:30 EST

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

HCMHUTCHMED2026-10-27 00:00 EST

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

STTKShattuck Labs2026-10-13 12:00 EST

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

IMMPImmutep Limited2026-11-05 13:00 EST

Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Eledon Pharmaceuticals, Inc.

Transplant Immunology Company Eledon Pharmaceuticals develops therapies intended to protect transplanted organs and cells while reducing reliance on broadly immunosuppressive regimens. Tegoprubart Tegoprubart is an anti-CD40L antibody designed to block a central co-stimulatory pathway involved in transplant rejection while preserving...

Recent company news

Stock data

Close
1.90 USD
Market cap
272.47M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States